JP2023552919A5 - - Google Patents

Info

Publication number
JP2023552919A5
JP2023552919A5 JP2023552151A JP2023552151A JP2023552919A5 JP 2023552919 A5 JP2023552919 A5 JP 2023552919A5 JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552919 A5 JP2023552919 A5 JP 2023552919A5
Authority
JP
Japan
Prior art keywords
seq
antibody
ryk
item
antibody derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552919A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058491 external-priority patent/WO2022103705A1/en
Publication of JP2023552919A publication Critical patent/JP2023552919A/ja
Publication of JP2023552919A5 publication Critical patent/JP2023552919A5/ja
Pending legal-status Critical Current

Links

JP2023552151A 2020-11-11 2021-11-08 Wnt受容体rykに対する抗体バリアント Pending JP2023552919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112616P 2020-11-11 2020-11-11
US63/112,616 2020-11-11
PCT/US2021/058491 WO2022103705A1 (en) 2020-11-11 2021-11-08 Antibody variants against wnt receptor ryk

Publications (2)

Publication Number Publication Date
JP2023552919A JP2023552919A (ja) 2023-12-19
JP2023552919A5 true JP2023552919A5 (cg-RX-API-DMAC7.html) 2024-10-24

Family

ID=81601681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552151A Pending JP2023552919A (ja) 2020-11-11 2021-11-08 Wnt受容体rykに対する抗体バリアント

Country Status (9)

Country Link
US (1) US20230416375A1 (cg-RX-API-DMAC7.html)
EP (1) EP4244259A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023552919A (cg-RX-API-DMAC7.html)
KR (1) KR20230107628A (cg-RX-API-DMAC7.html)
CN (1) CN117295767A (cg-RX-API-DMAC7.html)
AU (1) AU2021380681A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201419A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233683A (cg-RX-API-DMAC7.html)
WO (1) WO2022103705A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039910A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
EP2188310B1 (en) * 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
US9062101B2 (en) * 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9228023B2 (en) * 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014161037A1 (en) * 2013-04-03 2014-10-09 Peter Maccallum Cancer Institute Antibodies against human ryk and uses therefor
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
AU2016271111B2 (en) * 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
CA3039910A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies

Similar Documents

Publication Publication Date Title
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR102366682B1 (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
TWI432451B (zh) 新穎之抗igf-ir抗體及其用途
KR102308493B1 (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2022023182A (ja) 脱髄障害の治療のための併用療法および使用
JP6955721B2 (ja) RGMa結合タンパク質及びその使用
FR2888850A1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
JP7742433B2 (ja) 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
JP2020522512A5 (cg-RX-API-DMAC7.html)
Kanno et al. Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis
JP2023159355A (ja) Eltd1に対するモノクローナル抗体及びその使用
CN114945592A (zh) 抗-α-突触核蛋白单克隆抗体及其使用方法
CN111789954B (zh) 延缓衰老的方法和药物
CN118946581A (zh) 特异性结合api5蛋白的抗体
EP4082574A1 (en) Agent for preventing or treating acute-phase neuromyelitis optica
RU2822199C2 (ru) Способ предупреждения или лечения периферической нейропатии или боли, сопровождающей заболевание, при котором выявлена периферическая нейропатия или нарушение астроцитов
WO2025254163A1 (ja) 抗cadm1抗体およびその抗原結合断片
HK40118760A (en) Antibodies that specifically bind to api5 protein
KR20260062948A (ko) Ctla4/tigit 결합 단백질 및 이의 의학적 용도
KR20240063995A (ko) 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링
CN120112560A (zh) 用于治疗癌症的抗bssl抗体
CN110291110A (zh) 特异性结合pauf蛋白的抗体及其用途